Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Gynecologic 3Breast 3Gastrointestinal 1

Conditions

Breast Neoplasms 27Ovarian Neoplasms 6Neoplasm Metastasis 5Endometrial Neoplasms 5Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Neoplasms 3Small Cell Lung Carcinoma 2Neoplasms by Site 2Melanoma 2Hereditary Sensory and Autonomic Neuropathies 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Advanced Breast Cancer 2Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Recurrence 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1HR+/HER2- Breast Cancer 1Genetic Diseases, Inborn 1Fallopian Tube Neoplasms 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Colonic Neoplasms 1

Interventions

pembrolizumab 33Cisplatin 22Carboplatin 16Magnetic Resonance Spectroscopy 15Specimen Handling 12Cetuximab 12Radiotherapy, Intensity-Modulated 11Paclitaxel 9Platinum 8Nivolumab 81,2-diaminocyclohexaneplatinum II citrate 8atezolizumab 5Taxes 5Radiotherapy 5Docetaxel 5Biopsy 5Fluorouracil 4(225)Ac-DOTA-c(RGDyK) 4dostarlimab 3cemiplimab 3Radiotherapy, Image-Guided 3Radiation 3Fulvestrant 3Bevacizumab 3tislelizumab 2dehydroftorafur 2budigalimab 2amivantamab 2abemaciclib 2Tiragolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Fulvestrant × 30 days × Clear all
NCT05768139 2026-05-22

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT07109726 2026-05-22

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Terremoto Biosciences Inc.

Phase 1/2 Recruiting
205 enrolled
BreastGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06993844 2026-05-06

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Ensem Therapeutics

Phase 1/2 Recruiting
233 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡